Scale-up of a peptide therapy to help brain blood flow and inflammation in people at risk for Alzheimer’s-related dementias

Who could benefit from this research

What this research studies

This grant focuses on producing larger, GMP-grade batches of PNA5, a peptide designed to act on Mas receptors in the brain’s blood vessels and support better brain blood flow. The work aims to translate promising preclinical results into a manufacturable therapy that could eventually be tested in people at risk for ADRD and VCID. It is a Phase I SBIR project centered on manufacturing readiness and early safety signals, with the goal of enabling future human studies. By ensuring scalable, compliant production, the project helps pave the way for potential treatments that target vascular contributions to cognitive impairment.

Why it matters

Where this research is happening

• Proneurogen, INC.
  Tucson, United States Active

Researchers

• Principal investigator: Riley, Jeremy — Proneurogen, INC.
• Study coordinator: Riley, Jeremy

Related research

Other NIH-funded projects on the same topics.

• A brain-boosting peptide to help people at risk of vascular dementia and Alzheimer’s disease

  A new drug-like peptide (PNA5) is being studied to reduce brain inflammation and improve blood flow in people at risk for vascular dementia and Alzheimer's-related dementia.

  NIH research University of Arizona · Tucson, United States · NIH-11396379

• PNA5 — a new Mas receptor medicine to protect thinking in people at risk for vascular and Alzheimer's-related dementia

  Seeing whether the anti-inflammatory peptide PNA5 can be safely developed to help people with mild cognitive impairment who are at risk for vascular dementia or Alzheimer's-related dementia.

  NIH research University of Arizona · Tucson, United States · NIH-11169018

• A new treatment for cognitive impairment related to vascular dementia and Alzheimer's disease

  This study is testing a new treatment called PNA5 that could help improve thinking and memory for people at risk of dementia by reducing inflammation and boosting blood flow to the brain, making sure it's safe before moving on to the next steps.

  NIH research University of Arizona · Tucson, United States · NIH-10910078

• Global picture of dementia risk and memory loss across the world

  A large international effort gathers data from many studies to understand how dementia and memory problems develop around the world, using shared information to reveal patterns and risk factors.

  NIH research University of New South Wales · Sydney, Australia · NIH-11603263

• PNA5 for VCID and Alzheimer's Dementias: A first-in-human safety study

  A first-in-human trial tests a new drug, PNA5, to see if it is safe and tolerable for adults with vascular cognitive impairment and Alzheimer's-related dementias.

  NIH research University of Arizona · Tucson, United States · NIH-11442935

• Global picture of dementia and Alzheimer’s risk across populations

  A large international effort gathers health data from many cohorts to understand what increases or lowers the risk of dementia and Alzheimer's disease around the world.

  NIH research University of New South Wales · Sydney, Australia · NIH-11417899

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.